Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age

Conditions

• Influenza, Human

Interventions

• BIOLOGICAL: Experimental: IIV-A Investigational IIV-A will be administered as a single dose intramuscularly on Day 1
• BIOLOGICAL: Experimental: aIIV-B Investigational aIIV-B will be administered as a single dose intramuscularly on Day 1
• BIOLOGICAL: Experimental: aIIV-C Investigational aIIV-C will be administered as a single dose intramuscularly on Day 1
• BIOLOGICAL: Active Comparator: Licensed IIV IIV will be administered as a single dose intramuscularly on Day 1

Sponsor

Seqirus